Effects of GLP-1 receptor agonist treatment on pulmonary function and quality of life in obese patients with chronic obstructive pulmonary disease - A prospective, randomized, placebo-controlled, double-blinded, parallel group, two-center trial for the evaluation of the effect of Liraglutide 3 mg daily on chronic obstructive pulmonary disease.
Latest Information Update: 22 Apr 2020
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity
- Focus Pharmacodynamics
- 22 Apr 2020 Status changed from recruiting to completed.
- 28 Dec 2017 New trial record